Big pharma sues to block Illinois drug discount law
AbbVie and other drug makers sued Illinois Attorney General Kwame Raoul to block HB 2371, a law requiring manufacturers to provide 340B discounted drugs to commercial pharmacies working with covered entities. Plaintiffs argue it conflicts with federal 340B rules and shifts revenue burdens. Novartis filed a similar case in Illinois federal court.
How this was made
The 30-second read
Why it matters
The plaintiffs argue HB 2371 violates the Constitution’s supremacy clause by effectively changing federal 340B terms, forcing manufacturers to provide more discounted drugs and restricting data collection from covered entities.
Market read
This is a fresh legal challenge seeking an injunction against a new Illinois 340B contract pharmacy law, creating near-term uncertainty for 340B-related revenue and compliance for major pharma.
What to watch
Even if manufacturers lose, the practical impact may depend on how covered entities and commercial pharmacies operationalize contracts, and on any negotiated compliance timelines or settlements.
Background
Illinois Governor JB Pritzker signed HB 2371 to compel drug manufacturers to transfer 340B-priced drugs to commercial pharmacies working with covered entities, expanding beyond the federal 340B framework.
Ticker impact
AbbVie sued Illinois AG Raoul to block HB 2371, arguing the law forces more 340B-priced drug sales to commercial pharmacies than federal rules require.
Volatility risk around court filings and any injunction decision; direction depends on whether the court blocks enforcement.
The article is a fresh lawsuit seeking to stop enforcement, which can change expected 340B-related sales and compliance costs, but no court ruling is reported yet.
Novartis filed a nearly identical complaint, arguing Illinois HB 2371 cannot coexist with federal 340B law.
Potential downside bias if courts allow HB 2371 to proceed; otherwise relief if enforcement is blocked.
The newest fact is Novartis joining a legal challenge; however, the article provides no outcome, only arguments and requested relief.
Market effects
Could pressure 340B economics and contract pharmacy practices across states with similar laws, raising legal and compliance risk for large pharma.
Illinois is the immediate battleground; outcomes may influence other states’ enforcement and litigation strategies.
Primarily US policy risk, but it can affect multinational pharma earnings expectations tied to US government pricing programs.
Counterpoint
Courts may view HB 2371 as a permissible state contract pharmacy regulation, limiting manufacturers’ ability to restrict distribution and potentially supporting broader access.
Key entities
- companyAbbVie Inc.
Plaintiff seeking to block HB 2371 enforcement, arguing it forces additional 340B-priced sales beyond federal requirements.
- companyNovartis Pharmaceuticals
Plaintiff making a similar argument that HB 2371 conflicts with federal 340B law.
- companyAllergan Inc.
Joined the lawsuit challenging HB 2371’s expanded 340B contract pharmacy requirements.
- companyDurata Therapeutics Inc.
Joined the lawsuit as a plaintiff alongside AbbVie and others.
- governmentIllinois Attorney General Kwame Raoul
Named defendant, responsible for enforcement of HB 2371.
